Sellas Life Sciences

About SELLAS

SELLAS Life Sciences is a healthcare-oriented company with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. In other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide.

SELLAS is a Swiss based, development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various indications in cancer and the Central Nervous System (CNS). Sellas focuses on in-licensing drug candidates that are undergoing or have already completed initial (pre-) clinical testing and then seeks to further develop those drug candidates for commercial use.

Our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of Sellas. We strive to improve patients' quality of life through developing and commercializing cutting-edge innovative therapies.

Our management team has a proven track record of drug discovery, drug development and successful clinical trial coordination. In addition, the management team has been involved in bringing previous companies to the German DAX and US NASDAQ stock markets, successful out-licensing of drug candidates, co-development, R&D partnership with big pharma and creating multiple alliances with centers of excellence to accelerate drug discovery and development. The management team has developed cost-effective and time efficient ways of developing drug candidates to value inflection points.

Recent News

Catalent And SELLAS Sign Exclusive Agreement For Therapeutic Reprofiling Of Zolpidem

Somerset, N.J. – December 4, 2014 — Catalent Pharma Solutions, the leading global...
Read More →

SELLAS Life Sciences Group To Present at the Annual AEGIS Healthcare & Technology Conference

The Encore at Wynn Las Vegas: September 11th, 2014 Room: Chopin 2  – 3:30pm ...
Read More →